Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. "I think it could be a potentially ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.